SBIR Phase II: Early Detection of Pancreatic Cancer using Multiplex Protein Profiling

SBIR II 期：使用多重蛋白质分析早期检测胰腺癌

• 批准号: 2026113
• 负责人: Ilya Alexandrov
• 金额: $ 100万
• 依托单位: ActivSignal, LLC
• 依托单位国家: 美国
• 项目类别: Cooperative Agreement
• 财政年份: 2020
• 资助国家: 美国
• 起止时间: 2020-09-15 至 2024-08-31
• 项目状态: 已结题
• 来源: https://www.nsf.gov/awardsearch/showAward?AWD_ID=2026113&HistoricalAwards=false
• 关键词: SBIR; Phase; II; Early; Detection

The broader impact/commercial potential of this Small Business Innovation Research (SBIR) Phase II project is to improve clinical outcomes and quality-of-life for pancreatic cancer patients. Only 10% of pancreatic cancer survive five years after diagnosis because most cases are detected at later stages when clinical interventions are relatively ineffective. Earlier detection improves interventions, prevents unnecessary procedures arising from uncertain diagnosis, and leads to health system cost savings. Roughly 5 million individuals in the US are at higher risk, but there is no screening test available today for earlier stages, a surveillance market estimated at $3 B. This project will develop a diagnostic test for surveillance of people at high risk for developing pancreatic cancer, with methods potentially applicable to other types of cancer and other diseases.This Small Business Innovation Research (SBIR) Phase II project will advance a technology using a small blood sample to detect the functional state of multiple biological signaling pathways known to participate in cancer inception and progression. This technology can analyze these low abundance proteins at a low cost suitable for a widely adopted surveillance test. A purpose-built bioinformatic system analyses and compares the bio-signature identified by the assay across many individuals. This Phase II project will optimize the panel of protein targets in the assay to detect high-performing differential bio-signatures for early stages of the disease, and it will enhance the machine-learning-based matching methodology.This award reflects NSF's statutory mission and has been deemed worthy of support through evaluation using the Foundation's intellectual merit and broader impacts review criteria.

这项小企业创新研究（SBIR）二期项目的更广泛影响/商业潜力是改善胰腺癌患者的临床结果和生活质量。只有10%的胰腺癌患者在确诊后存活5年，因为大多数病例是在临床干预相对无效的晚期才被发现的。早期发现可改善干预措施，防止因诊断不确定而产生不必要的程序，并节省卫生系统费用。在美国，大约有500万人处于更高的风险中，但目前还没有针对早期阶段的筛查测试，这一监测市场估计为30亿美元。该项目将开发一种诊断测试，用于监测患胰腺癌的高风险人群，其方法可能适用于其他类型的癌症和其他疾病。这项小型企业创新研究（SBIR）二期项目将推进一项技术，该技术使用少量血液样本来检测已知参与癌症发生和进展的多种生物信号通路的功能状态。该技术可以以低成本分析这些低丰度蛋白质，适用于广泛采用的监测测试。一个专门建立的生物信息学系统分析和比较许多个体的生物特征。该二期项目将优化检测中的蛋白质靶点面板，以检测疾病早期阶段的高性能差异生物特征，并将增强基于机器学习的匹配方法。该奖项反映了美国国家科学基金会的法定使命，并通过使用基金会的知识价值和更广泛的影响审查标准进行评估，被认为值得支持。